Mangoceuticals (MGRX) Liabilities and Shareholders Equity (2022 - 2026)

Mangoceuticals (MGRX) has 5 years of Liabilities and Shareholders Equity data on file, last reported at $14.4 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 33.58% year-over-year to $14.4 million; the trailing twelve-month figure through Mar 2026 stood at $67.9 million (up 1.13% YoY), and the FY2025 full-year result was $16.1 million, up 4.68% from the prior year.
• Liabilities and Shareholders Equity retreated to $14.4 million in Q1 2026, from $16.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $21.8 million in Q1 2025 to a low of $301447.0 in Q1 2024.
• A 5-year average of $10.5 million and a median of $14.6 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity tumbled 92.67% in 2024 and jumped 7116.48% in 2025, its largest moves.
• Tracing MGRX's Liabilities and Shareholders Equity over 5 years: stood at $1.0 million in 2022, then advanced by 4.74% to $1.1 million in 2023, then surged by 1362.75% to $15.4 million in 2024, then gained by 4.68% to $16.1 million in 2025, then decreased by 10.2% to $14.4 million in 2026.
• Business Quant data shows MGRX's Liabilities and Shareholders Equity at $14.4 million in Q1 2026, $16.1 million in Q4 2025, and $16.5 million in Q3 2025.